Regeneron and Avalanche Biotechnologies sign development collaboration Regeneron and Avalanche Biotechnologies announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron. Avalanche will receive an upfront cash payment, contingent payments of up to $640M upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products. The collaboration covers up to eight distinct therapeutic targets, and Regeneron will have exclusive worldwide rights for each product it moves forward in clinical development.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.